Injectable NAD+ involves different questions than oral NR or NMN. People looking for information on lyophilized NAD+ vials, compounding injection preparations, or pre-filled pens often want to know what amounts were used in published studies, how different vial strengths translate to concentration, what reconstitution is, how injectable preparations are generally administered, and how prepared solutions are stored. However, there is a significant gap in the available evidence. Most NAD+ injection preparations currently available are compounded or research-use products, rather than drugs approved by the FDA or EMA and supplied with a single standardized, regulatory-verified dosing and preparation protocol.
Therefore, there is no single universal injection dose of NAD+, reconstitution ratio, administration frequency, or post-reconstitution shelf life that can be safely applied to every product.
Available human studies are also much more limited than the current commercial market might suggest.
Published research has focused primarily on the intravenous administration of NAD+ in supervised clinical settings. By contrast, controlled data regarding self-administered subcutaneous NAD+, intramuscular NAD+, and commercial NAD+ pens remain very limited.
That is why this guide focuses on what has actually been used in published research. It also explains the basic pharmaceutical principles regarding injectable NAD+ preparations and separates research findings from commercial and online community protocols.
Specific product instructions provided by a physician or the pharmacy preparing a compounded medication should always take precedence. The concentration, excipients, sterility requirements, stability, and the formulation itself can vary significantly between preparations.
NAD+ injection dosage chart: what was actually studied?
In published studies involving humans, very different doses of NAD+ were used, depending on the specific clinical context.
This is one of the reasons why the size of a commercial vial should never be interpreted as a verified dose.
In one controlled clinical trial, a relatively small daily amount of intravenously administered NAD+ was used.
In turn, a retrospective analysis of the real-world use of commercial IV therapy involved a significantly larger amount.
Commercial vials, on the other hand, may contain significantly more NAD+ than a single dose used in any of these studies.
| Context | Applied dose | Frequency | Duration | Application route |
|---|---|---|---|---|
| Randomized placebo-controlled trial in patients with heart failure/ischemic cardiomyopathy [1] | 10 mg/day | Once a day | 7 days | Intravenously |
| Retrospective study of the tolerance of commercial IV therapy in real-world conditions [2] | 500 mg/day | Once a day | 4 consecutive days | Intravenously |
| Typical sizes of commercial vials, not verified clinical doses | 100 mg, 500 mg or 1000 mg per vial | Depending on the product/protocol | Depending on the product/protocol | They may be offered for subcutaneous, intramuscular, or intravenous administration. |
The differences are immediately visible.
A daily dose of 10 mg was used in the randomized clinical trial.
In the retrospectively analyzed commercial intravenous application, however, 500 mg per day was administered, which is fifty times the daily amount used in the controlled heart failure study. [1,2]
None of these values should be automatically considered as the correct dose for another application.
Populations, objectives, formulations, administration conditions, and study designs were different.
Commercial vial sizes are another source of misunderstanding.
A vial containing 500 mg or 1000 mg describes the total nominal amount of the substance contained in the package.
This does not mean that the entire vial constitutes a single dose.
It also does not specify what the final concentration of the preparation should be, how often it should be administered, or whether the given amount has been verified for subcutaneous or intramuscular administration.
Most importantly, controlled human studies have not established a standardized protocol for self-administering NAD+ subcutaneously using commercial pens or reconstituted vials.
Therefore, NAD+ dosing tables available on the Internet typically reflect the practices of individual physicians, compounding pharmacies, manufacturer instructions, or user habits, rather than a single clinically verified regimen.
What does subcutaneous administration of NAD+ mean?
Subcutaneous administration means the introduction of a medication or preparation into the layer of adipose tissue located beneath the skin, rather than directly into a vein or muscle.
This is a well-established route of administration for many approved drugs.
However, the existence of standard subcutaneous injection techniques does not mean that a specific NAD+ formulation has been clinically verified for this route of administration.
This distinction is important.
Most published research on NAD+ injections has utilized supervised intravenous administration.
Controlled studies directly evaluating self-administered subcutaneous NAD+ remain scarce.
Subcutaneous preparations may also differ in concentration, excipients, pH, sterility requirements, and device design.
Therefore, the proper administration technique, allowed injection sites, volume, type of device, and dose should be based on the instructions of a doctor, pharmacist, or the manufacturer responsible for the specific formulation, rather than a general protocol for NAD+.
The basic safety rules for injectable drugs still apply.
Hands, equipment, and the site of administration should be maintained in appropriate hygienic conditions.
With repeated subcutaneous injections, rotation of the injection sites is usually necessary if this method of administration has been recommended.
Single-use needles should not be reused.
Used needles and other sharp objects require proper disposal.
A solution that unexpectedly becomes cloudy, changes color, appears contaminated, or contains visible particles should not automatically be considered suitable for use.
These are general principles for injectable medications, not NAD+-specific evidence.
Each person who has not previously used the prescribed self-injection medication should receive practical instructions from an appropriately qualified healthcare professional or pharmacist before attempting self-administration.
What does the reconstitution of NAD+ with bacteriostatic water mean?
Reconstitution means the transformation of a lyophilized, or freeze-dried, powder into a liquid preparation using a specific sterile solvent.
This is not a process unique to NAD+.
Many pharmaceutical injection products are stored as a dry powder, as this state can provide greater stability than continuous storage of the active substance dissolved in water.
Bacteriostatic water is one of the possible solvents used for certain multi-dose injection preparations.
It contains sterile water and a small amount of benzyl alcohol, the purpose of which is to limit microbial growth after repeated punctures of the vial.
However, this does not mean that bacteriostatic water is suitable for every NAD+ preparation.
The right solvent depends on the specific formulation.
Some compounded preparations may require sterile water, bacteriostatic water, saline, another vehicle, or a solvent system specially prepared by the pharmacy.
Why does the reconstitution volume matter?
The amount of solvent affects the concentration of the final solution.
The basic relationship is simple:
final concentration = total amount of NAD+ in the vial ÷ final fluid volume.
The more concentrated preparation contains more NAD+ per milliliter.
The more diluted preparation contains less NAD+ in one milliliter.
The total nominal amount of NAD+ originally present in the vial does not change simply because a larger or smaller amount of solvent is used.
However, this basic calculation should not be treated as a recommendation for preparing the product.
Changing the concentration may also affect the injection volume, tolerability, pH-related properties, device compatibility, and potentially stability.
Therefore, the choice of reconstitution volume is not purely a mathematical exercise.
It should comply with the specific formulation instructions provided by the dispensing pharmacy or the manufacturer.
Why is there no universal NAD+ reconstitution ratio?
Commercial NAD+ supplements vary from one another.
Two vials marked with the same number of milligrams can differ in purity, excipients, chemical form, required pH, intended route of administration, and concentration specification.
Scientific literature also does not specify a single, universally verified ratio of bacteriostatic water to NAD+ for the commonly sold 100 mg, 500 mg, or 1000 mg vials intended for self-injection.
General pharmaceutical rules therefore explain what reconstitution involves.
However, they do not establish a universal recipe.
The prepared injection solution must meet the requirements specified for the specific formulation.
If instructions are missing or unclear, the appropriate solution is to obtain information from the dispensing pharmacy or an appropriately qualified healthcare professional, rather than using general proportions found on the internet.
NAD+ Pens: what are they and how do they differ from vials?
NAD+ pens are injection devices designed for more convenient, repeated subcutaneous administration.
Some products are supplied pre-filled.
Others use replaceable cartridges.
Depending on the design, the user can select the quantity using a dial, a numbered setting, or a click-based mechanism.
This form can reduce some of the manual tasks associated with traditional multi-dose vials.
NAD+ patches, however, are not standardized among manufacturers.
The delivered dose per click, concentration in the cartridge, needle compatibility, method of preparing the pen before use, storage conditions, and shelf life after opening may vary.
Therefore, the setting used in one pen cannot be automatically interpreted the same way in another device.
Pens used to administer well-known medications, such as insulin or GLP-1 receptor agonists, undergo extensive device-specific validation.
Commercial NAD+ pens do not have to possess a comparable evidence base verified by regulatory authorities.
For this reason, the specific pen's instructions remain crucial.
General rules for using pens include using the device only with compatible sterile components, checking the selected dose before administration, rotating injection sites for repeated subcutaneous injections if recommended, and storing the device in accordance with the requirements of the specific formulation.
This is general information only.
They do not replace device-specific instructions or professional training.
How long can NAD+ be stored after reconstitution?
The lyophilized compound may behave differently after reconstitution.
After adding water, several new stability issues arise.
Chemical degradation may occur.
Oxidation or hydrolysis processes may gain greater importance.
Multiple punctures of the vial introduce additional microbiological issues.
Some formulations may also be affected by temperature and light exposure.
Because of this, reconstituted injection preparations usually have a specified shelf life after preparation.
For many multi-dose pharmaceutical preparations containing bacteriostatic water, storage periods of approximately two to four weeks can be encountered in general compounding practice. [3]
However, this range should not be treated as a verified shelf life of NAD+.
The number of published studies specifically determining how long a specific reconstituted NAD+ preparation maintains adequate chemical activity, sterility, purity, and an acceptable level of degradation products is limited.
Individual formulations may therefore have different post-preparation shelf lives.
Refrigeration
Many reconstituted injectable preparations require refrigeration.
This rule is also often applied to compounded NAD+ preparations.
However, the required temperature range should be based on the specific product manual.
The preparation should not be automatically stored in a refrigerator, frozen, or repeatedly moved between different temperatures solely based on assumptions regarding peptides or other substances for injection.
NAD+ itself is not a peptide, and stability requirements should be defined for the specific formulation.
Exposure to light
For some compounded preparations, protection against excessive light exposure may also be recommended.
Again, this depends on the stability data for the specific formulation.
The original packaging and container provided by the pharmacy are usually designed taking into account the intended storage conditions.
Saving the preparation date
For each reconstituted multi-dose product, it is important to accurately record the date of preparation or first use.
This helps prevent the use of a multi-dose vial past the expiration date specified by the pharmacy or manufacturer.
Changes in the appearance of the solution
Unexpected turbidity, discoloration, precipitation, visible particles, damaged packaging, or suspected contamination are warning signs.
The correct appearance of the solution does not confirm its sterility or chemical stability.
Similarly, exceeding the post-preparation expiration date should not be ignored just because the liquid remains transparent.
Storage instructions provided by the pharmacy or manufacturer remain a more reliable standard.
How often was injectable NAD+ used in clinical studies?
Dosing frequency is another area where clinical trials and commercial practice differ significantly.
Available supervised human studies have typically used short periods of daily administration.
In a randomized heart failure trial, NAD+ was administered intravenously once daily for seven days at 10 mg per day. [1]
In a retrospective analysis of commercial IV use, participants received 500 mg daily for four consecutive days. [2]
These protocols answered specific research questions.
They do not establish a universal long-term NAD+ application scheme.
None of these studies determined whether weekly injections, administration every other day, long-term maintenance treatment, or repeated monthly cycles are better.
Controlled clinical trials have also not established a single verified maintenance subcutaneous regimen.
Commercial self-administration protocols may involve daily use, alternate-day use, several times a week, or other cyclical schedules.
These schemes must be clearly distinguished from the protocols used in published studies.
They usually come from product instructions, prescription pharmacy practice, individual doctor recommendations, or user habits.
Currently, there is insufficient evidence to conclude that one of these regimens provides better NAD+ exposure, more favorable clinical outcomes, or greater long-term safety.
Total exposure also matters.
A smaller amount given more often and a larger amount used less frequently are not automatically equivalent.
Without pharmacokinetic data for a specific route of administration and formulation, comparing the total weekly milligram amount alone does not allow for the determination of bioequivalence.
Therefore, frequency, dose, formulation, and route of administration should be considered together rather than as separate, interchangeable variables.
Comparison of evidence regarding different routes of NAD+ administration
| Question | NAD+ intravenous | NAD+ subcutaneously | NAD+ intramuscularly | Peny NAD+ |
|---|---|---|---|---|
| Published human experiments | Yes | Limited | Limited | Very limited |
| Controlled dose studies | Some, under specific clinical conditions [1] | Insufficiently established | Insufficiently established | Lack of standardization as a category |
| Commercial availability | Yes | Yes | Yes | Yes |
| Universal, standardized dose | Not | Not | Not | Not |
| Standardized reconstitution protocol | Formulation-dependent | Formulation-dependent | Formulation-dependent | Usually device/formulation dependent |
| Data on long-term, repeated use | Limited | Very limited | Very limited | Very limited |
| Proven direct anti-aging/wellness efficacy | Not | Not | Not | Not |
The most important conclusion is that commercial availability is much broader than the scope of clinical validation.
Frequently asked questions about NAD+ dosage and reconstitution for injection
What is the typical NAD+ injection dose?
There is no single, universally verified dose of NAD+ for injection. Published human studies have used vastly different intravenous amounts, including 10 mg daily for seven days in one randomized heart failure study and 500 mg daily for four consecutive days in a retrospectively analyzed commercial IV application. [1,2]
These protocols should not be interpreted as standardized NAD+ dosages for subcutaneous, intramuscular, wellness, or self-administration purposes.
Does a 500 mg NAD+ vial mean a 500 mg dose?
No.
A 500 mg vial specifies the nominal total amount of NAD+ contained in the vial.
It does not specify the amount intended for a single administration, the final concentration after preparation, the frequency of use, or an evidence-based treatment regimen.
Is a 1000 mg NAD+ vial stronger than a 500 mg vial?
A 1,000-mg vial contains twice the nominal total mass of NAD+ as a 500-mg vial, but this does not automatically mean that a single dose will be „stronger.”.
The final concentration and the actual administered amount depend on the preparation method and the instructions for the specific product.
How much bacteriostatic water should be added to NAD+?
There is no single verified volume suitable for every NAD+ vial.
The proper solvent and final concentration depend on the specific formulation, the amount in the vial, the planned route of administration, the excipients, and the pharmacy instructions.
Reconstitution should therefore be carried out in accordance with the instructions provided with the specific product, rather than based on a general ratio found online.
Can NAD+ be reconstituted with bacteriostatic water?
Some compounding preparations may require bacteriostatic water, while others may require a different sterile solvent.
You should not automatically assume that bacteriostatic water is appropriate just because the product is supplied as a lyophilized powder.
Does adding more water change the amount of NAD+?
Adding more solvent changes the concentration, not the total nominal amount of NAD+ originally present in the vial.
The more diluted preparation contains fewer milligrams in one milliliter, whereas the more concentrated one contains more milligrams per milliliter. However, the proper concentration should result from the instructions for the specific product.
Can NAD+ be administered subcutaneously?
NAD+ preparations intended for subcutaneous administration are commercially available, but controlled human studies regarding standardized subcutaneous dosing, pharmacokinetics, frequency of use, and long-term safety are significantly more limited than the literature concerning supervised intravenous administration.
Therefore, the commercial preparation should be used solely in accordance with its specific medical or pharmaceutical instructions.
Is intramuscular NAD+ better than subcutaneous NAD+?
Currently, there are no robust controlled human studies confirming the superiority of intramuscular NAD+ over subcutaneous NAD+.
There is a lack of direct studies comparing the pharmacokinetics and outcomes for these two routes of administration.
How long can NAD+ be stored after reconstitution?
In the published literature, a single universal shelf life for NAD+ after reconstitution has not been established.
General sources on multidose preparations sometimes give expiration periods calculated in weeks, but the exact timeline depends on the specific formulation, solvent, sterility conditions, container, and stability data provided by the pharmacy or manufacturer. [3]
Should reconstituted NAD+ be stored in the refrigerator?
Many compounded NAD+ preparations are supplied with a recommendation to store them in the refrigerator after reconstitution.
However, the exact requirements should come from the specific product instructions or the pharmacy.
Storage conditions should not be generalized to all formulations.
Can NAD+ be used daily?
Daily short-term intravenous administration has been used in human studies. [1,2]
However, this does not confirm the safety or efficacy of long-term, daily use of NAD+ subcutaneously, intramuscularly, or via a pen.
Long-term frequency of use remains insufficiently understood.
Limitations of current research
The biggest limitation is that published research on injectable NAD+ does not accurately reflect a large portion of the modern commercial market.
Controlled human studies primarily focused on supervised intravenous administration.
Self-administered subcutaneous preparations, injection pens, and commercial dosing regimens have not been studied in an equally thorough manner.
Another limitation is the huge difference between the studied quantities.
One randomized study used 10 mg per day.
In a retrospective study of commercial IV use, however, 500 mg per day was evaluated. [1,2]
These values cannot simply be placed on a single universal dose-response scale because the studies involved different populations, objectives, designs, and clinical conditions.
Reconstitution constitutes another significant gap in the evidence.
Scientific literature does not specify a single standardized amount of bacteriostatic water for commonly sold NAD+ vials of various strengths.
General concentration calculations can explain how dilution works, but they do not determine which concentration is appropriate for a specific compounded preparation.
Similar uncertainty applies to stability after reconstitution.
General pharmaceutical sources outline the principles for handling reconstituted multidose preparations, but the number of peer-reviewed stability studies on NAD+ allowing for the establishment of a single universal storage period remains limited. [3]
Commercial pens introduce additional volatility.
Individual devices may contain different concentrations and deliver different amounts at a specific setting or click.
Therefore, the existence of a universal conversion factor for pen devices should not be assumed.
Long-term safety also remains insufficiently understood.
Short periods of supervised treatment do not allow the effects of repeated subcutaneous or intramuscular administration over many months or years to be determined.
Finally, commercial application should not be equated with clinical validation.
The availability of 100 mg, 500 mg, or 1000 mg vials, injection pens, or repeated clinical protocols shows that such products exist on the market.
However, it does not prove that specific potencies, regimens, or routes of administration have been confirmed as optimal in randomized controlled trials.
Disclaimer
This article is for educational and scientific-informational purposes only. It does not constitute medical advice, a prescription, individual dosage recommendations, reconstitution instructions, injection training, or a recommendation for the use of NAD+ in injection form.
The dosages discussed above describe the amounts used in specific published studies and should not be interpreted as standardized, approved, or appropriate for self-administration. Injectable NAD+ preparations are not approved by the FDA or EMA for anti-aging, wellness, energy enhancement, or the prevention or treatment of diseases.
Compounded NAD+ preparations may vary in concentration, required solvent, excipients, sterility requirements, storage conditions, device design, and expiration date. Therefore, reconstitution and administration should be carried out in accordance with the instructions provided by the attending physician, the authorized pharmacy compounding the medication, or the manufacturer responsible for the specific formulation. Improper preparation or administration of the injection may lead to contamination of the preparation, infection, tissue damage, dosage errors, or other complications.
References
[1] American Journal of Cardiovascular Drugs. (2026). Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: A randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12779688/
[2] Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582
[3] Empower Pharmacy. (2025). How to prepare a lyophilized powder for injection. Empower Pharmacy Patient Resources. https://www.empowerpharmacy.com/compound-medication/medication-instructions/how-to-prepare-lyophilized-powder-for-injection/